Results 161 to 170 of about 4,378 (208)
Some of the next articles are maybe not open access.
2018
One of the most challenging issues in oncology research and treatment is identifying oncogenic drivers within an individual patient's tumor which can be directly targeted by a clinically available therapeutic drug. In this context, gene fusions as one important example of genetic aberrations leading to carcinogenesis follow the widely accepted concept ...
Stephanie, Berger +2 more
openaire +2 more sources
One of the most challenging issues in oncology research and treatment is identifying oncogenic drivers within an individual patient's tumor which can be directly targeted by a clinically available therapeutic drug. In this context, gene fusions as one important example of genetic aberrations leading to carcinogenesis follow the widely accepted concept ...
Stephanie, Berger +2 more
openaire +2 more sources
Separation Science Plus
A specific, sensitive, and accurate chiral analytical method was developed to separate enantiomers and isomers of Larotrectinib using chiral high‐performance liquid chromatography (HPLC).
Chandra Sekhara Rao Boddala +3 more
semanticscholar +1 more source
A specific, sensitive, and accurate chiral analytical method was developed to separate enantiomers and isomers of Larotrectinib using chiral high‐performance liquid chromatography (HPLC).
Chandra Sekhara Rao Boddala +3 more
semanticscholar +1 more source
Larotrectinib: A Targeted Therapy for Solid Tumors
Clinical Journal of Oncology Nursing, 2021Although neurotrophic tyrosine receptor kinase (NTRK) gene fusions are not common in most cancers, they are present in more than 90% of some rare tumors. The U.S. Food and Drug Administration has approved larotrectinib for patients with NTRK gene fusion-positive cancers that meet certain criteria.
Gabriela, Mota-George +1 more
openaire +2 more sources
Larotrectinib Use in A Patient with A Diffuse High-Grade Glioma with NTRK2 Fusion
International Journal of Clinical Case Reports and ReviewsHigh-grade gliomas, particularly in the pineal region, present challenges due to their aggressive nature and the lack of established treatment regimens.
Casey B. Brown
semanticscholar +1 more source
Journal of Clinical Oncology
PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline ...
T. Laetsch +16 more
semanticscholar +1 more source
PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline ...
T. Laetsch +16 more
semanticscholar +1 more source
Journal of Clinical Oncology
3066 Background: Larotrectinib (laro) is the first-in-class, highly selective, TRK inhibitor approved for tumor- and age-agnostic use in TRK fusion cancers.
A. Drilon +19 more
semanticscholar +1 more source
3066 Background: Larotrectinib (laro) is the first-in-class, highly selective, TRK inhibitor approved for tumor- and age-agnostic use in TRK fusion cancers.
A. Drilon +19 more
semanticscholar +1 more source